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Abstract
As health care consumes a growing share of GDP, the demand for better evidence regarding
the effects of health care treatments and how these vary across individuals is increasing. Estimating
this with observational data is difficult given the endogeneity of treatment decisions. But because
the random assignment clinical trials (RACTs) used in the FDA approval process only estimate
average health effects and do not consider spending, there is no good alternative. In this study
we use administrative data from California’s Medicaid program to estimate the impact of HIV
antiretroviral treatments (ARVs). We use data on health care utilization to proxy for health status
and exploit the rapid takeup of ARVs following their FDA approval. Our estimate of a 68 percent
average mortality rate reduction is in line with the results from RACTs. We also find that the
ARVs lowered short-term health care spending by reducing expenditures on other categories of
medical care. Combining these two effects we estimate the cost per life year saved at $19,000.
Our results suggest an alternative method for estimating the real-world effects of new treatments
that is especially well-suited to those treatments that diffuse rapidly following their approval.
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I. Introduction
During the 2004 calendar year, health care expenditures accounted for 16 percent
of GDP in the U.S., with this share twice as large as the corresponding value in
1970 and predicted to exceed 20 percent by 2015. Previous research has
suggested that a key contributor to rising health care costs is the introduction and
diffusion of new and more expensive treatments (Newhouse, 1992; Cutler,
2004).1 To the extent that these treatments provide health benefits that are
sufficiently large to justify the cost increases, there may be little cause for
concern. However, because most consumers of health care in the U.S. have
health insurance, which partially or fully insulates them from price differences
when choosing between alternative treatments, it is plausible that there is
excessive use of certain treatments.2 Similarly, health care providers may have
incentives to advocate for certain treatments over others, which could exacerbate
or attenuate this phenomenon.3 Even absent these issues, both consumers and
providers often have imperfect information about the effects of alternative
treatments.
As health care spending continues to grow, it is likely that the demand for
better evidence regarding the effects of new treatments in real-world settings will
increase (Garber, 2004). At present, health care providers rely to a large extent on
the results from random assignment clinical trials (RACTs), which are the
dominant method for estimating causal relationships in medicine. While these
trials make important contributions to knowledge, they have a number of
important limitations. Perhaps most importantly, they rarely consider the effect of
a treatment on expenditures but instead focus only on health effects.
Additionally, results from the trials may not apply to real-world settings, where
adherence to a treatment regimen may be different from in the controlled
environment of an RACT. Finally, RACTs are well-suited to estimating average
effects but not how those effects vary across patients. It is plausible that a
treatment is very effective on average but has little effect on the margin, a
phenomenon referred to as “flat of the curve medicine” (Fuchs, 2004).4
1

Of course, new treatments can lower health care spending as well through health improvements
that reduce the demand for other types of medical care (Lichtenberg, 2001).
2
See Garber, Jones, and Romer (2006) for an analysis of why for similar reasons health insurance
and certain regulatory features can lead to excessive innovation in this sector.
3
See Kessler and McClellan (1996) for one such example, in which physicians respond a greater
threat of being sued for malpractice by providing more treatments than their counterparts at lower
risk.
4
See Chan and Hamilton (2006) for a comprehensive discussion of the limitations of medical
researchers’ analysis and interpretation of clinical trial data. An additional limitation of clinical
trials not mentioned in that study is that there can be placebo effects, which can lead to biased
estimates as shown in a recent study by Malani (2006).
1
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Researchers must therefore use alternative methods and data sources to
estimate the impact of health care treatments in real world settings. One possible
strategy is to use data on health care utilization generated by government
programs such as Medicaid and Medicare. These claims data sets have the
advantage of large sample sizes, which can be important for obtaining precise
estimates of treatment impacts. They also have the advantage of capturing
treatment patterns in the real world.
The key obstacle to obtaining reliable estimates when using claims data is
that treatment is endogenous. Individuals who take a certain treatment may differ
in important ways from their observably similar counterparts who do not.
Previous researchers have accounted for this issue in a variety of ways. One
prominent study used a patient's distance from a hospital as a source of variation
in treatment (McClellan et al, 1994). In that study, the authors demonstrate that
individuals who live closer to the hospital are more likely to receive intensive
treatment, and use this variation to estimate the marginal effect of invasive
treatments. However, as the authors note, this method is not well-suited to
estimating the average effect of a health care treatment.
In this paper, we propose an alternative approach to estimating the effect
of health care treatments that allows us to estimate the average effect of a new
treatment soon after its introduction and how the effect varies across individuals.
More specifically, we use several years of claims, eligibility, and mortality data
from California’s Medicaid program to estimate the effect of new HIV
antiretroviral treatments (ARVs) on both health care spending and health
outcomes.
We select these treatments as our case study for three main reasons. First,
these treatments are differentially used by beneficiaries of the Medicaid program,
with almost half of U.S. residents with HIV/AIDS insured by Medicaid
(Bhattacharya et al, 2003), and thus our estimates are more likely to be reflective
of overall impacts. Second, several RACTs have demonstrated the average health
benefits of ARVs, and thus we have a baseline against which we can compare our
estimates. To the extent that we replicate the RACT results for average health
effects, we can be more confident that our estimates for spending and for how
both health and expenditure effects vary across individuals are accurate.5 And
finally, because these treatments diffused rapidly, our estimates are less likely to
be contaminated by changes in the population of individuals with HIV/AIDS.
We account for endogenous treatment decisions in two ways. First, we
5

It is important to note that here we do not consider producer surplus, which as Philipson and Jena
(2006) point out can lead to underestimates of the benefits of new medical technologies.
However, their estimates for ARVs suggest that the value of consumers' health benefits exceeded
producer surplus by a factor of twenty, and thus at least for this category of treatments we are
omitting only a small fraction of the social benefit.
DOI: 10.2202/1558-9544.1102
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utilize data from before and after the introduction of several new ARVs and
exploit the fact that there were sharp changes in their use immediately following
their approval. By controlling for the pre-existing trends in our outcome variables
of interest, we can obtain credible estimates for the average short-term effect of
these treatments as they are rapidly diffusing. Second, we utilize the detailed
information on health care utilization to construct proxies for health status. This
allows us to estimate the variation across individuals in effectiveness of treatment
by comparing individuals who take the treatments with their observably similar
counterparts from the period just prior to FDA approval.
An analysis of trends in the average values of our key outcome variables
of interest demonstrates that, prior to the approval of Epivir and three protease
inhibitors (hereafter Epivir/PI) in late 1995, quarterly mortality rates and average
spending among California Medicaid recipients with HIV/AIDS were fairly stable
at 7 percent and $5400, respectively. But within 1.5 years of the approval of
Epivir/PI, the fraction of our sample taking one or more of these ARVs had
increased to almost 60 percent while the quarterly mortality rate had fallen to 2
percent. This decline coincides closely with trends at the national level,
suggesting that the low-income beneficiaries of the Medicaid program were
approximately as successful as other U.S. residents with HIV/AIDS in complying
with the recommended treatment regimen. During the same period, average
quarterly Medicaid expenditures declined by almost $400, with a substantial
increase in prescription drug spending more than offset by spending on
hospitalizations and other health care services.
While these changes in average outcomes are striking, they shed little light
on the extent to which the effects varied across individuals. We therefore next
turn to individual-level data, where we demonstrate that controlling for pretreatment health status substantially increases our estimate for the average effect
of the treatments on mortality probabilities. Moreover, we uncover substantial
heterogeneity in this effect, with the sickest patients deriving the largest health
benefits. Our findings for the effect of the treatments on expenditures also reveal
substantial heterogeneity, with large reductions in spending for the sickest
patients but significant increases for healthier patients. The mechanism for this is
that the use of the new treatments increased pharmaceutical spending but reduced
the need for hospitalizations and other types of medical care. Healthier patients
had little other medical care to offset and thus the increase ARVs increased total
spending on them.
In the final section of our paper, we investigate the effect of the new
treatments on long-term Medicaid spending, life expectancy, and the
corresponding cost per life-year saved.6 The new treatments reduced quarterly
6

These treatments may have influenced other outcome variables as well. For example,
Lakdawalla et al. (2006) find that ARVs increase risky behavior such as unprotected sex and
3
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Medicaid spending by an average of 16 percent but increased life expectancy by a
factor of three. Combining these two effects leads us to estimate the cost per life
year saved of the four treatments introduced in late 1995 and early 1996 at close
to $19,000, well within the range of what is considered to be cost effective.
The results from this study suggest an alternative method for utilizing
claims data to evaluate the impact of new health care treatments on both spending
and health. This method is most well-suited to evaluating the effect of treatments
that diffuse rapidly such as the ARVs considered here.
II. Background on HIV/AIDS and Antiretroviral Treatments
AIDS is a chronic disease that damages, and ultimately destroys, an individual’s
immune system. AIDS is caused by HIV, an infection that kills the body’s "CD4
cells", a type of white blood cell that helps the body fight off infections. When
this epidemic first appeared, providers could only treat opportunistic illnesses
resulting from the weakened immune system rather than attack the virus itself.
This changed with the entry of Retrovir (AZT) to the market in 1987. This drug
was the first one approved by the FDA in the therapeutic class known as NRTIs
(nucleoside reverse transcriptase inhibitors). Despite the entry of three additional
NRTIs from 1991 to 1994, use of these drugs among AIDS patients actually
declined from 1992 through 1995. This trend reversed following the approval of
Epivir and three drugs from a new class known as protease inhibitors (PIs) in late
1995 and early 1996. The first NNRTI (non-nucleoside reverse transcriptase
inhibitor) was approved in June of 1996. Twelve additional drugs were approved
in the seven years from 1997 to 2003 (Table 1).
The release of Epivir/PI spawned the use of highly active antiretroviral
therapy (HAART), which is the simultaneous use of two or more ARVs to treat
HIV. The optimal time to initiate HAART depends both on the strength of the
patient’s immune system and on the concentration of HIV in the patient’s blood.
Current guidelines recommend HAART for all patients with less than 200 CD4
cells per cubic millimeter of blood and suggest that all patients with CD4 cell
counts between 200 and 350 be offered treatment (NIH, 2004; Yeni et al., 2002).
Thus those HIV-positive individuals who take the drugs will tend to be sicker
than their counterparts who do not. In a short period after the approval of
Epivir/PI, HAART became the standard treatment for those infected with HIV.
The sharp increase in the use of the drugs coincided with a substantial decline in
the mortality rate among AIDS patients.7 According to data from the U.S.
intravenous drug use. While important, we consider these outcomes and some others (e.g.
pharmaceutical firm profits) to be outside the scope of the current study.
7
Individuals with HIV are defined as having AIDS once their CD4 count falls below 200 or once
they are diagnosed with an AIDS-defining illness. The main benefit of starting HAART early is
DOI: 10.2202/1558-9544.1102
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Centers for Disease Control, the mortality rate for individuals with AIDS fell by
70 percent between 1995 and 1998.
A large number of studies, some using randomized research designs
(Hammer et al., 1997; Delta Coordinating Committee, 2001; Floridia et al., 2002)
and others using observational data with detailed clinical information (Palella et
al., 1998; Detels et al., 1998; CASCADE Collaboration, 2003) investigated the
life saving benefits of the new ARVs.8 All of these studies found that the new
treatments generated statistically significant reductions in mortality. For example,
in an RACT examining the effectiveness of one protease inhibitor in combination
with Retrovir and Epivir, Hammer et al. (1997) found that 48-week mortality rates
were 55 percent lower among those taking a protease inhibitor. Palella et al.
(1998) used observational data for 1255 patients in eight U.S. cities to examine
the impact of ARVs on mortality. Controlling for demographic characteristics
and CD4 count levels prior to treatment, the authors found that mortality fell by
more than 70 percent among those using protease inhibitors with two or more
NRTIs.9
Demonstrating that we could replicate the results from RACTs or studies
with more detailed clinical information would potentially expand the types of
questions that can be addressed with claims data. We therefore view estimates
from these previous studies as a useful benchmark. If the treatments are similarly
effective for those on Medicaid and if these individuals adhere well to the
treatment regimens then we should detect a similar average mortality effect.

that it can prevent both the degradation of the immune system and the elevation of viral loads.
The main costs are that patients often experience severe side effects and they can also develop
drug resistance, thereby reducing future treatment options.
8
Lichtenberg (2003) uses aggregate, national-level data for the U.S. to estimate the effect of ARV
approvals.
9
There are no RACTs of which we are aware that compare the use of both Epivir and PI with the
use of neither.
5
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Table 1: Prescription Drugs Approved for Treatment of HIV Infection by 12/31/03
FDA

First script
in

Class

Brand
Name

Appr. Date

claims data

Ingredients

NRTI
NRTI
NRTI
NRTI
NRTI
NRTI
NRTI
NRTI
NRTI
NRTI

Retrovir
Videx
Hivid
Zerit
Epivir
Combivir*
Ziagen
Trizivir**
Viread
Emtriva

3/19/1987
10/9/1991
6/19/1992
6/24/1994
11/17/1995
9/27/1997
12/17/1998
11/14/2000
10/26/2001
7/2/2003

1/2/1993
1/4/1993
1/4/1993
8/6/1994
11/27/1995
10/17/1997
12/18/1998
12/1/2000
11/1/2001
7/16/2003

zidovudine
didanosine
zalcitabine
stavudine
lamivudine
lamivudine, zidovudine
abacavir
abacavir, zidovudine, lamivudine
tenofovir disoproxil fumarate
emtricitabine

PI
PI
PI
PI
PI
PI
PI
PI

Invirase
Norvir
Crixivan
Viracept
Fortovase
Agenerase
Kaletra
Lexiva

12/6/1995
3/1/1996
3/13/1996
3/14/1997
11/7/1997
4/15/1999
9/15/2000
10/20/2003

12/11/1995
3/7/1996
3/26/1996
3/19/1997
11/18/1997
4/26/1999
9/20/2000
11/11/2003

saquinavir mesylate
ritonavir
indinavir
nelfinavir mesylate
saquinavir
amprenavir
lopinavir and ritonavir
fosamprenavir calcium

NNRTI
NNRTI
NNRTI

Viramune
Rescriptor
Sustiva

6/21/1996
4/4/1997
9/17/1998

8/10/1996
4/25/1997
9/23/1998

nevirapine
delavirdine
efavirenz

FI

Fuzeon

3/13/2003

4/8/2003

enfuvirtide

Source for drug list and approval dates: US FDA at http://www.fda.gov/oashi/aids/virals.html
* Combivir is a combination of Epivir and Retrovir
** Trizivir is a combination of Epivir, Retrovir, and Ziagen

DOI: 10.2202/1558-9544.1102
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III. Constructing the Analysis Files
A. The California Medicaid Claims and Eligibility Data
We utilize claims and eligibility data for a random 24 percent sample of Medicaid
recipients from the state of California to estimate the effect of ARVs. Individuals
can qualify for the means-tested Medicaid program through several different
channels, with the most common reasons in California being the receipt of
Temporary Assistance to Needy Families (TANF) or Supplemental Security
Income (SSI) benefits. In our data there are 4.03 million people eligible for
Medicaid in at least one month from 1993 to 2003. The eligibility files contain
demographic information including gender, month and year of birth, and race.
Additionally, there are two variables in each month that allow us to determine
whether each individual is dually eligible for health insurance through Medicare
or enrolled in a Medicaid managed care plan.10
The claims data includes all fee-for-service payments made from January
of 1993 until June of 2004, though because there is often a lag in processing the
claims, we consider utilization through the end of 2003. There are three types of
claims in our data. Inpatient claims are generated for admissions to hospitals and
long-term care facilities and include information about the patient’s primary and
secondary diagnosis, the dates of service, and the amount paid by Medicaid.
Outpatient claims have similar data about payments to physicians, emergency
rooms, and other health care providers. Finally, prescription drug claims provide
data on payments made to pharmacies for drugs covered by Medicaid. Each
pharmacy claim includes an eleven-digit National Drug Code that allows us to
determine the drug and the dosage amount. All three types of claims include the
patient’s Medicaid identifier (an encrypted social security number), which we
match to the eligibility files.
Finally, our claims and eligibility data11 has been merged to death records
from the California Center for Health Statistics for the 1993 through 2001 period.
These records identify date and cause of death for all California residents, though
8 percent of our sample cannot be linked because they do not have a valid
(encrypted) social security number.
B. Defining the HIV/AIDS Sample
A number of previous researchers have used Medicaid claims data to construct
samples of HIV/AIDS patients (Eichner and Kahn, 2001; Morin et al., 2002).
10

Many Medicaid recipients are also eligible for Medicare, either because they are over the age of
65 or because they receive benefits from the Social Security Disability Insurance program.
11
This data was obtained from the California Department of Health Services' Medical Care
Statistics Section. See Duggan (2005) for a detailed description of this data. There is a 24 percent
sample because the 20 and 5 percent samples that the state provides partially overlap.
7
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Following this research, we use ICD-9 diagnosis codes on the Medicaid inpatient
and outpatient claims to determine whether individuals are diagnosed with this
illness. To reduce the possibility of false positives, we restrict attention to patients
with two or more non-prescription HIV/AIDS claims.12 This algorithm yields a
sample of 12,932 individuals who have one or more HIV/AIDS claims, are
eligible for Medicaid at some point during our study period, have a valid social
security number, and have consistent age and gender information across years in
the eligibility files.13
Although our Medicaid claims data contain a rich set of information, it
does have some important limitations. First, our data is for just one state and thus
our results may not generalize to Medicaid recipients elsewhere in the country.
Second, we lose patients who temporarily or permanently exit because they
become ineligible for Medicaid.14 Third, we do not know when patients were first
diagnosed with HIV or AIDS but instead only the date of their first Medicaid
HIV/AIDS claim during our study period. Fourth, claims data do not contain
diagnostic information about patients such as CD4 cell counts or HIV viral loads.
This information is important because it indicates who is recommended to receive
ARVs. Fifth, we do not have Medicare expenditure data for people also eligible
for that program and we will therefore understate health care expenditures by the
government for this group.15 And sixth, we have incomplete utilization data for
patients enrolled in a Medicaid managed care plan and thus exclude them from
our analyses.
One final limitation to our analysis sample that must be considered in the
results that follow is that we only have data for Medicaid recipients. While
Medicaid insured approximately half of all California residents with HIV/AIDS
during our study period (Bhattacharya et al., 2003), our sample does not include
individuals who are uninsured or receive health insurance from another source.
Perhaps the most relevant source for a person prior to or immediately following
his/her enrollment in Medicaid is the AIDS Drug Assistance Program (ADAP),
which was introduced in 1996. This program subsidizes the purchase of ARVs
for low-income individuals who are without another source of health insurance.
Because the introduction of this program may have affected the entry to or exit
from the Medicaid program, we estimate several specifications below that restrict
12

False negatives are also a possible concern, though as we describe below the number in our
sample is similar to what we would expect given that approximately half of California residents
with HIV/AIDS are on Medicaid.
13
Research by Rosenblum et al., (1993) using Medicaid claims data has found that this algorithm
captures the vast majority of recipients diagnosed with HIV/AIDS.
14
Fewer than 2 percent of the sample exits the sample per quarter and this exit rate declines during
our study period. For example it falls from 1.96% in the last quarter of 1995 to 1.42% in the first
quarter of 1998.
15
Medicare did not cover prescription drugs for dual eligibles during our study period.
DOI: 10.2202/1558-9544.1102
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only to those enrolled in Medicaid and diagnosed with HIV in the year prior to the
introduction of ADAP.16
C.
Sample Characteristics
On the left-hand axis in Figure 1, we plot the number of Medicaid recipients in
our sample who were alive at the beginning of half-year periods starting in
January of 1994. The patients in each half-year cell had their first HIV/AIDS
claim by the end of that period although they may have been enrolled in Medicaid
for some time before that date. Roughly one-fourth of the sample appears in the
first half-year of the time period and the sample grows steadily after that date. On
the right-hand axis of the figure, we graph the total number of people living with
AIDS in California17 at the end of each six month period as reported by the U.S.
Centers for Disease Control in their publication HIV/AIDS Surveillance Report.
These two series track one another quite closely. Our numbers suggest that
roughly 52 percent of people living with AIDS in California are on Medicaid,18 a
number close to the national average (Bhattacharya et al., 2003). Similarly the
number of individuals in our sample grows at an almost identical rate to the
statewide total (58 percent for both from 1994 to 2001). Given the possible
limitations with using claims data outlined above, our algorithm for identifying
Medicaid recipients with HIV/AIDS appears to work quite well.19

16

The ADAP program gave some states an incentive to change the stringency of their Medicaid
eligibility requirements. Recent research suggests that states with more stringent Medicaid
eligibility thresholds had higher mortality rates among affected individuals with HIV/AIDS
(Ghosh et al, 2007).
17
We should note that our sample includes not only patients with AIDS but also some who are just
HIV-positive. Unfortunately, in most years California only reported to the CDC the number of
people living with AIDS, not the number with HIV. Thus in one respect it is plausible that the
patients in our sample would be healthier than the typical AIDS patient in California. However,
most of the individuals in our sample qualify for Medicaid through the means-tested Supplemental
Security Income (SSI) program. Thus they must be in relatively poor health to meet SSI’s medical
eligibility criteria. As we document below, the death rates for our sample are substantially higher
than for non-Medicaid AIDS patients in California. Therefore, comparing trends in the number of
HIV/AIDS patients on Medicaid to overall trends of AIDS patients seems a reasonable
compromise given the available data.
18
Consider the first half of 1994 when there are 3,237 individuals in our sample. To estimate the
number on Medicaid with HIV/AIDS one must multiply this by (1/.24). Additionally we must
multiply by 1.058 to account for the exclusion of those with an invalid SSN. This yields 14,270,
which is 52.0% of the statewide total of 27,454.
19
One possible concern with focusing just on Medicaid recipients is that the incentive to enroll in
the program will change after new treatments become available (Goldman et al., 2001), raising the
possibility of composition bias. The fact that our series tracks closely with the total number in the
state suggests this is not too problematic.
9
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Figure 1: HIV/AIDS Cases in the 24% Medicaid Sample and # Living with AIDS in CA
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In Figure 2, we graph half-year mortality rates for the Medicaid recipients
in our sample during the 1994-2001 period and compare this with the
corresponding mortality rate among all California AIDS patients. Death rates in
our sample are approximately 2 percentage points higher on average, indicating
that Medicaid recipients are in worse health. Additionally, the timing and
magnitude of the declines in mortality for the two groups are similar.
In Table 2, we report descriptive information for our sample in four years:
1994, 1997, 2000 and 2003. In constructing this sample we drop the 1,063
individuals who live in one of the eight counties that moved its Medicaid
recipients into a county-organized health system during our study period because
our claims data would often be incomplete for them. We also drop the 1,802
individuals with one or more months in a Medicaid managed care plan during our
eleven-year study period.20 This leaves us with a final sample of 10,067
HIV/AIDS patients. As the table shows, the annual mortality rate in the sample
fell from 23.0 percent in 1994 to 5.2 percent in 2000, contributing to a large
increase in the average age of the sample. The fraction of the population under 40
20

The lack of data for patients in managed care could be problematic if it leads to changes in the
composition of our sample over time, though the fact that the number of individuals in our sample
tracks the number statewide with AIDS quite closely (Figure 1) suggests that this issue is not too
problematic.
DOI: 10.2202/1558-9544.1102
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fell from 50 percent in 1994 to 28 percent nine years later. During our study
period the fraction of the sample that is black and female increased by 47 and 19
percent, respectively.
In the bottom half of the table, we report information about health care
utilization in our sample. Almost 48 percent of our sample had an inpatient stay
in 1994 and this number fell to 28 percent during the next nine years. Annual
inpatient spending fell by an even larger percentage from $7125 to $3510. In
contrast, annual outpatient spending increased slightly while spending on
prescription drugs tripled, driven primarily by the increased use of ARVs.
Although average annual spending on prescription drugs increased by $8,000 by
the end of the study period in 2003, total annual spending increased by just
$4,800.21 The fraction of HIV/AIDS patients who are eligible for Medicare
increased from 28 to 45 percent, with this change likely contributing to the fall in
Medicaid spending on inpatient care given that Medicare covers most inpatient
costs for dual eligibles.
Figure 2: Half-Year Mortality Rate for AIDS Patients
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Expenditure data cited here and elsewhere in the paper are adjusted to December, 2001 dollars
using the Bureau of Labor Statistics' Consumer Price Index for Urban consumers (CPI-U).
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Table 2: Summary Statistics for the Medicaid HIV/AIDS Sample
Average Age
% Ages 0-17
% Ages 18-29
% Ages 30-39
% Ages 40-49
% Ages 50-64
% Ages 65+
% Black
% Female
Inpatient Spending
Outpatient Spending
RX Spending
Total Spending
% Die in Year
% Any Inpatient
Eligible Months
% Medicare
# in Sample

1994
38.4
2.5%
12.0%
44.1%
29.3%
10.0%
2.1%
21.1%
15.2%
7125
5091
4122
16338
23.0%
47.8%
8.9
28.0%
3221

1997
40.7
2.6%
8.5%
38.7%
33.1%
13.4%
3.8%
23.4%
21.3%
4309
4870
7769
16948
7.5%
39.8%
10.1
39.2%
3687

2000
43.0
2.5%
4.4%
32.0%
37.7%
19.2%
4.3%
24.5%
21.8%
3900
5007
11913
20820
5.2%
30.0%
10.4
43.3%
4275

2003
45.1
2.2%
3.8%
21.9%
41.8%
25.3%
4.9%
25.0%
22.3%
3510
5455
12120
21084
27.9%
10.8
44.7%
4976

Includes Medicaid-eligible individuals in the 24 percent CA sample with 1 or more
HIV/AIDS claims in current or previous year. Excludes those with one or more
months in a Medicaid managed care plan or in one of the eight counties with a
county-organized health system.

IV. The Impact of HIV Antiretroviral Treatments: A Graphical Presentation
The FDA’s approval of Epivir in November of 1995 and of three protease
inhibitors during the next four months coincided with a sharp decline in the
mortality rate among the Medicaid recipients in our sample. As Figure 2
demonstrates, from the latter half of 1995 to the same period in 1997, the sixmonth mortality rate among California Medicaid recipients diagnosed with
HIV/AIDS fell by 70 percent, from 11.3 to 3.4 percent. During the next four
years the mortality rate in our sample declined gradually and was equal to 2.8
percent in the second half of 2001.
Figure 3 depicts the fraction of individuals in the sample filling at least
one prescription for an ARV in the quarter. From the third quarter of 1995 to the
second quarter of 1997, this fraction more than doubled, increasing from 29 to 59
percent. As Figure 4 shows, this growth was driven by an increase in the use of
Epivir/PI, with 56 percent of our sample taking one or more of these treatments in
the second quarter of 1997. There were no significant changes in utilization for
DOI: 10.2202/1558-9544.1102
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other ARVs. Taken together, the series depicted in Figures 2, 3, and 4 strongly
suggest that Epivir/PI was the primary cause of the sharp decline in mortality
rates observed during our study period.
This is more easily represented in Figure 5, where on the left vertical axis,
we report the fraction of patients that are using either Epivir or protease inhibitors,
and on the right vertical axis, we report the patient quarterly mortality rate. There
are three things to highlight in this graph. First, notice that prior to the first
quarter of 1996, quarterly mortality rates had been trending down slightly.
Second, as Epivir/PI use increased from zero to 56 percent between the fourth
quarter of 1995 and the second quarter of 1997, quarterly mortality rates fell by
72 percent, from 6.7 percent to 2.0 percent. As Epivir/PI use stabilized in mid1997, so did mortality rates. Between mid 1997 and the end of our study period,
mortality rates varied between 1.4 and 2.0 percent with no obvious trend.
Figure 3: Fraction of CA Medicaid Sample Taking 1+ HIV Drugs in Each Quarter
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Figure 4: Diffusion of Epivir and Protease Inhibitors: 1994Q1 - 2003Q4
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Figure 5: Quarterly Mortality Rate and Use of PI/Epivir
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The potential importance of Epivir/PI as an explanation for the decline in
mortality is most easily illustrated with a simple time series model in which we
regressed the first-difference in quarterly mortality rates on the first difference in
quarterly Epivir/PI use among HIV/AIDS patients in our sample during the 19942001 period. The coefficient on the change in Epivir/PI use is -0.079 (with a
standard error of 0.015), which implies an average reduction of 7.9 percentage
points in the quarterly mortality rate.22 This is actually greater than the mortality
rate in our sample just prior to the approval of these treatments, which is not so
surprising given that the individuals who took the new ARVs are likely to have
been in worse health and thus have higher baseline mortality rates.
Given the major improvements in health resulting from the use of
Epivir/PI, it is plausible that the treatments partially or fully paid for themselves
by reducing the demand for hospitalizations and other health care services.
Figure 6 plots average Medicaid spending in our sample along with average
spending on both prescription drugs and all other health care services. As is clear
from the figure, average spending on prescription drugs increased substantially
following the introduction of Epivir/PI, increasing from $1391 in the third quarter
of 1995 to $2505 just two years later. But spending on all other services fell by
an even greater amount, so that average quarterly spending declined by 8 percent
($5401 to $5030) from late 1995 to 1997. As we demonstrate below, this change
in average Medicaid expenditures masks important changes in its overall
distribution.
We also investigated whether the treatments affected the quarterly exit rate
from the program for reasons other than mortality (e.g. return to work) and found
little evidence to support this as shown in Appendix Figure 1. This is especially
true in the two years just after the approval of Epivir-PI. This suggests that the
composition of our sample is not changing too dramatically during the period that
is the focus of our empirical analysis.23

22

It is worth noting that many taking Epivir and/or a protease inhibitor were also taking one or
more other ARVs. Thus our estimates may to some extent be capturing the effect of a
combination of new and existing treatments.
23
One noteworthy change shown in Table 2 is in the fraction of the sample that is female, which
increased from 15 to 21 percent from 1994 to 1997. However, this fraction was already trending
up prior to the approval of Epivir-PI.
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Figure 6: Average Quarterly Spending in the Medicaid HIV/AIDS Sample
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V. The Impact of the New Treatments on Mortality: Individual-Level
Evidence
In this section we estimate the impact of Epivir/PI use on mortality using
individual-level claims data. There are two key factors we must consider when
constructing an econometric model. First, individuals who are in worse health are
both more likely to die and to use these treatments. Failing to account for this
would lead us to underestimate the health benefits of the treatments. Second, the
effect of the treatment is likely to vary across individuals, with more severe
patients deriving greater benefits. These two considerations motivate a model of
the following type for the effect of taking a treatment Z in the current period on
health status H in the next period:
(1) H j ,t +1 = μ * H jt + γ ( H jt ) * Z jt + θ * X jt + ε j ,t +1
In this equation, Hjt represents individual j’s health status in period t and Zjt is an
indicator that equals one if person j takes the treatment in period t and zero
otherwise. The average effect of the treatment is assumed to vary only with the
individual’s health status according to the function γ ( H jt ) 24. Other background
24

We define this function below to include both a "main effect" and an effect that varies linearly
with health status.
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characteristics such as gender, age, and race, all of which are potentially
important determinants of changes in health status, are controlled for in the vector
Xjt.
A. Estimating Health Status
To construct a proxy for health status Hjt, we exploit the diagnosis and treatment
information contained in our Medicaid claims data. We recognize that our data is
not perfect for this, as it does not include detailed clinical information such as
CD4 counts or viral loads. Our data does however contain a record of every
health care treatment paid for by the Medicaid program for the individuals in our
sample. In this section, we investigate whether the claims data can capture
variation across individuals in their mortality probabilities in the period just prior
to the release of Epivir/PI. To the extent that this is successful, we can then use
these predicted probabilities to investigate differences in the utilization and in the
impact of Epivir/PI as suggested by equation (1).
We are especially interested in the severity of each individual's HIVAIDS
illness, as this is by far the most common cause of death for the individuals in our
sample prior to the introduction of Epivir/PI and will influence whether
individuals are encouraged to take Epivir/PI soon after it becomes available. We
therefore focus attention on inpatient and outpatient claims with a primary or
secondary diagnosis of HIV/AIDS when estimating linear probability models of
the following form:
(2) D j ,t +1 = β 0 + β1 * HIV _ IPjt + β 2 * HIV _ OPjt + β 3 * HIV _ PAID jt + ωt +1 + ε j ,t +1
In this model, the variable D j ,t +1 is equal to 1 if individual j dies in quarter t+1
and zero otherwise. The variables HIV_IPjt and HIV_OPjt represent the number
of inpatient and outpatient claims, respectively, with a primary or secondary
diagnosis of HIV/AIDS for person j in quarter t. Individuals with more severe
cases of HIV/AIDS would presumably have more contact with the health care
system and thus more Medicaid claims. Of course, not all claims are equal, with
some reflecting payment for intensive services (e.g. emergency room visits or
hospital stays) and others simply payment for annual checkups. In an effort to
account for this, we also include a variable HIV_PAIDjt, which is equal to total
Medicaid spending (in thousands of dollars) for inpatient and outpatient claims
with a primary or secondary diagnosis of HIV/AIDS.25
We estimate this model using data for all four quarters of 1994,
approximately one year prior to the introduction of Epivir/PI. The number of
individuals in this estimation sample is 2781 and the number of observations is
25

Our results in this section and in the subsequent sections were very similar if we used a richer
set of utilization controls to predict quarterly mortality rates.
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7854. 26 The estimates for β1, β2, and β3 using 1994 data are .0332 (se = .0126),
.0027 (se = .0003), and .0034 (se = .0015), respectively, with the estimate for β0
of .0426 (se = .0031). All three estimates are positive and statistically significant,
suggesting that our utilization measures capture important dimensions of health
status. We then use the coefficient estimates from equation (2) to calculate a
predicted quarterly mortality probability – our proxy for health status - for each
individual in the sample in every one of the next eight quarters. This two year
period (from the first quarter of 1995 to the final quarter of 1996) includes the
period leading up to and immediately following the introduction of Epivir/PI and
is the focus of our subsequent analyses.
Before proceeding to these analyses, we test the predictive power of our
proxy in two ways. We first investigate whether it is significantly positively
related with quarterly mortality outcomes just prior to the release of Epivir/PI by
estimating specifications of the following type using data from the first three
quarters of 1995:
(3) D j ,t +1 = λDˆ j ,t +1 + φX jt + π t +1 + ξ j ,t +1
In this equation, Dˆ
is individual j’s predicted mortality probability in quarter
j ,t +1

t+1 and D j ,t +1 is the actual mortality outcome for j in that same quarter, which
equals one if the person dies in quarter t+1 and zero otherwise. The vector X jt
includes a set of control variables for the person’s age, gender, race, and Medicare
eligibility. π t +1 represents a set of eight indicator variables for each quarter that
we consider to control for common changes over time in mortality probabilities.
The equations are estimated as linear probability models.
The results presented in the first column of Table 3 demonstrate that our
proxy for HIV/AIDS severity is a powerful predictor of mortality during the 1995
calendar year. Specifically the coefficient estimate for λ is 1.042 (t-statistic of
11.2) and is not significantly different from 1. Interestingly there are also
statistically significant differences in mortality probabilities by age and gender,
even after controlling for our measure of health status. For example, women are
significantly less likely to die and the mortality probability generally increases
with age.

26

For a particular person-quarter observation to be included in this estimation sample, the person
must be eligible for Medicaid during all three months in the quarter and still be alive at the end of
the quarter.
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Table 3: Determinants of Mortality and of Epivir/PI Utilization
Mortality

PI-Epivir

(1)

(2)

HIV Severity

1.042***
(0.093)

0.979***
(0.129)

Female

-1.557**
(0.658)

-0.124***
(0.019)

Black

-0.113
(0.675)

-0.126***
(0.018)

Age 15-24

-2.621**
(1.050)

-0.198***
(0.043)

Age 25-34

-1.385**
(0.663)

-0.021
(0.018)

Age 45-54

1.515*
(0.886)

0.002
(0.022)

Age 55-64

1.141
(1.464)

-0.074**
(0.035)

Age 65+

-1.312
(1.358)

-0.302***
(0.042)

Medicare

0.812
(0.635)

0.126***
(0.017)

Quarters Included
# Observations
Quarter Effects?
R-squared
Mean of Dep Var
# of Individuals

95Q1-95Q3
6504
Yes
0.0779
0.062
2711

96Q1-96Q4
10523
Yes
0.0986
0.428
3280

Sample includes all individuals with one or more HIV/AIDS claims in the quarter or
in a previous quarter and who are eligible for Medicaid and still alive at the end of
the quarter. Unit of observation is the person-quarter. All specifications are
estimated as linear probability models and include quarter fixed effects. Standard
errors are clustered by individual.

We next investigate whether – as expected – Dˆ j ,t +1 is significantly
positively related with the likelihood that an individual in our sample takes
Epivir/PI during the 1996 calendar year. To examine this question, we estimate a
model similar to equation (3) but use as the outcome of interest an indicator that
equals 1 if person j was taking either Epivir/PI in quarter t+1. The coefficient
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estimate on the predicted mortality probability Dˆ j ,t +1 of 0.979 (t-statistic of 7.6)
displayed in the second column of Table 3 reveals that sicker patients were the
ones most likely to select into the new treatment following its release. The results
presented in this column also demonstrate that there are significant differences by
gender, age, and race in the takeup of the new treatments.
The results described in this section demonstrate that the Medicaid claims
data can be used to estimate the health status of individuals with HIV/AIDS. We
next use this proxy to estimate the effect of the new pharmaceutical treatments
released in late 1995 and early 1996 on mortality outcomes and the extent to
which this effect varied across individuals.
B. Individual-Level Estimates
In this section we estimate the effect of Epivir/PI on mortality outcomes for the
individuals in our sample. We focus on the two year period from the first quarter
of 1995 to the final quarter of 1996. This gives us four quarters of information
prior to the introduction of Epivir/PI and four quarters when the new treatments
were rapidly diffusing. There are four reasons for focusing on this two-year
period even though we have several more years of data. First, it allows us to
contrast outcomes for individuals with HIV/AIDS prior to the introduction of the
new treatments with their observably similar counterparts one year later. Second,
it is readily apparent from the trends in mortality that this period is the most
important one, with mortality rates falling by almost 60 percent in the year
following the release of Epivir/PI. Third, there were no other HIV treatments
released in 1995 and 1996, except for one that had very low utilization (1.0 and
3.3 percent in the third and fourth quarters, respectively, of 1996). This reduces
the possibility that changes in other treatment patterns might bias our results. The
fourth and most important reason is that, once the new treatments were released,
the distribution of health status in our Medicaid sample begins to change rapidly.
As a result of this, the relationship between treatment patterns and health status
may also have changed, which would lead our proxy to be a less reliable measure
of health over time.
To estimate the effect of Epivir/PI on mortality, we estimate specifications
that allow the effect of the treatment to vary across individuals as a function of the
predicted mortality probability Dˆ j ,t +1 . Specifically, we assume that the treatment
effect γ from equation (1) above is a linear function of an individual's predicted
mortality probability when estimating linear probability models of the following
type:
(4) D
= θ * E + θ * Dˆ
+ θ * E * Dˆ
+ ρX + ω + ξ
j ,t +1

1

jt

2

j ,t +1

3

jt

j ,t +1
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In this equation, E jt is equal to 1 if individual j fills one or more Epivir or
protease inhibitor prescriptions in quarter t and zero otherwise. The main effect
of the treatment is captured by the parameter θ1 and the interaction of this effect
with health status by θ3 .27 The vector of indicator variables ωt+1 is included to
control for common changes over time in mortality.
Our prediction that the treatments reduce mortality rates by a larger
amount for sicker patients seems reasonable given the trends summarized in
Figure 7. In this figure, we plot quarterly mortality rates for the sickest 20 percent
of patients (quintile 5), the next sickest 20 percent (quintile 4), and all other
patients. As the figure demonstrates, beginning in the first quarter of 1996,
quarterly mortality rates in our sample fell substantially, with the largest drop
apparent for the sickest patients. By the first quarter of 1997, quarterly mortality
rates had fallen by 70 percent in the fifth quintile (from 19.8 to 5.2 percent) and
by 66 percent in quintile four (from 5.6 to 1.9 percent). Consistent with this, the
fraction taking Epivir/PI in the fourth quarter of 1996 was approximately similar
in the two groups at 68 and 71 percent, respectively. In contrast, just 40 percent
of those in quintiles 1 through 3 filled a prescription for Epivir or protease
inhibitors during this same quarter.
Figure 7: Quarterly Mortality Rates by HIV/AIDS Severity: 1995Q1 - 1997Q1
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Thus the treatment effect function γ from equation (1) is equal to θ1 + θ3 *

Dˆ j ,t +1 .
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Before proceeding to the results, it is worth considering two possible
sources of bias that could be present when estimating this model. First, our
measure of health status is not perfect. To the extent that two individuals with
identical values of Dˆ j ,t +1 have different values of E jt , it is plausible that the
person taking the treatment is on average in worse health. This would most likely
lead us to understate the health benefits of the treatment. Second, even if our
proxy for health status were perfect, if the effect of the treatments varies across
individuals and individuals with the highest perceived benefits self-select into
treatment, we might overstate the average benefits of the treatment. We think this
second source of bias is unlikely to be important, especially right after the
treatments were released when patients and their health care providers had little
experience with the new treatments. In an effort to reduce both potential sources
of bias, our identification strategy essentially uses HIV/AIDS patients from before
the treatments were available as a comparison group for observably similar
individuals who had the option to take Epivir/PI after it reached the market.
The empirical results summarized in Table 4 examine the impact of
Epivir/PI use on mortality. The equation we estimate is similar to (4) above and
the estimation sample is constructed from the sample of patients described in
section 3, though because we are considering a two-year period rather than the
full eleven-year period the number of individuals considered here is lower. For
person j to be included in our estimation sample in quarter t, he/she must be
eligible for Medicaid in all three months of the current quarter and in all three
months of the previous quarter, and must still be alive at the end of the current
quarter. There are 15,882 quarterly observations for 3,413 individuals, with the
number of observations for each person ranging from one to eight. All
specifications are estimated as linear probability models and include eight quarter
indicators.
In the first column of Table 4, we report results that include only the time
effects and the variable indicating whether the patient takes Epivir/PI in the
current quarter. Because sicker patients were likely to take these treatments, the
magnitude of this estimate is likely to be biased down.
The statistically
significant point estimate of -.0085 suggests that the treatments reduce mortality
rates by less than one percentage point. This is much smaller in magnitude than
the time series estimate presented above or than the estimates from random
assignment clinical trials mentioned in section two.
The inclusion of
demographic variables and the fraction of months in which the person was
enrolled in Medicare lead to a small increase in this coefficient estimate to -.0113.
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Table 4: The Heterogeneous Impact of Epivir/PI on Mortality
Any Epivir/PI

(1)

(2)

(3)

(4)

(5)

(6)

-.0085**
(.0038)

-.0113***
(.0039)

-.0280***
(.0039)

-.0285***
(.0039)

-.0360***
(.0040)

.0115
(.0076)

.9731***
(.0658)

.9166***
(.0742)

.7819***
(.0753)

.9438***
(.0822)

HIV Severity
Any Epivir/PI *
HIV Severity

-.6387***
(.1092)

Previous HIV
Severity

.1051
(.0665)

.0400
(.0658)

.0489
(.0639)

Female

-.0202***
(.0038)

-.0126***
(.0036)

-.0123***
(.0036)

-.0141***
(.0037)

-.0130***
(.0037)

Black

-.0015
(.0041)

-.0023
(.0036)

-.0024
(.0039)

-.0012
(.0038)

-.0012
(.0038)

Age 15-24

-.0505***
(.0061)

-.0362***
(.0065)

-.0358***
(.0066)

-.0332***
(.0077)

-.0326***
(.0079)

Age 25-34

-.0182***
(.0053)

-.0189***
(.0050)

-.0190***
(.0050)

-.0174***
(.0050)

-.0179***
(.0049)

Age 35-44

-.0088*
(.0051)

-.0106**
(.0048)

-.0107**
(.0048)

-.0090
(.0048)

-.0093**
(.0048)

Age 55-64

-.0082
(.0086)

-.0054
(.0087)

-.0054
(.0088)

-.0069
(.0086)

-.0062
(.0083)

Age 65+

-.0083
(.0098)

-.0019
(.0102)

-.0017
(.0102)

0.0005
(.0099)

.0021
(.0101)

Medicare

-.0085***
(.0037)

.0058
(.0033)

.0063*
(.0036)

.0010
(.0036)

.0011
(.0035)

# Other RX Claims

.0016***
(.0002)

0.0016***
(.0002)

# Other Outpatient
Claims

.0002**
(.0001)

.0002***
(.0001)

# Other Inpatient
Claims

.0005
(.0008)

.0006
(.0008)

95Q115882
Yes
0.0919
3413

95Q115882
Yes
0.0978
3413

Quarters Included
# Observations
Quarter Effects?
R-squared
# Individuals

95Q115882
Yes
0.0057
3413

95Q115882
Yes
0.0092
3413

95Q115882
Yes
0.0779
3413

95Q115882
Yes
0.0783
3413

Sample includes all individuals with one or more HIV/AIDS claims in the quarter or in a previous
quarter and who are eligible for Medicaid in all three months of this quarter, all three months of the
previous quarter, and still alive at the end of the quarter. Unit of observation is the person-quarter. All
specifications are estimated as linear probability models and include quarter fixed effects. Standard
errors are clustered by individual and included in parentheses.
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Neither of these first two specifications includes our proxy for health
status. In the third specification we add the predicted mortality measure defined
above to the set of explanatory variables. The inclusion of this variable leads to
an almost threefold increase in the magnitude of the estimate for the impact of
Epivir/PI to -.0280. The coefficient estimate of 0.9731 for the predicted mortality
probability Dˆ j ,t +1 is not significantly different from one. Because our measure of
health status is undoubtedly measured with error, we include the value of j's
predicted mortality probability from the preceding quarter in the fourth
specification. Interestingly the inclusion of this variable has virtually no impact
on the other coefficient estimates, with the estimate for the effect of Epivir/PI
increasing slightly in magnitude to -.0285. In the fifth specification we add
controls for the utilization of medical care for other conditions, which should to
some extent capture additional dimensions of health status that are not captured
by Dˆ j ,t +1 . The coefficients on these additional variables have the expected
(positive) sign and their inclusion increases our estimate for the effect of Epivir/PI
to -.0360, which is more than four times greater than the estimate from column
one.
In the sixth and final specification, we allow the effect of the treatments to
vary with severity by interacting the treatment indicator E jt with Dˆ j ,t +1 . If
patients in worse health experience larger reductions in their mortality
probabilities, one would expect a negative estimate for the coefficient on this
interaction term. And this is indeed what we find, with an estimate of -0.6387 for
θ3 that is significant at the one percent level. Including this interaction term
reduces the magnitude of our estimate for θ1 to a statistically insignificant .0115,
implying that relatively healthy patients experienced no significant mortality
decline as a result of taking the treatment.
One possible concern with our estimates not mentioned above concerns
the change in health care utilization induced by Epivir/PI. To the extent the
treatments reduce the number of hospital admissions or physician visits, this will
reduce patients’ predicted mortality probabilities but this indirect effect would not
be captured by the estimates for θ1 and θ3. To account for this possibility, we
estimated a companion set of specifications in which we “freeze” each patient’s
predicted mortality probability at its value in the fourth quarter of 1995. Our
results using this alternative specification yielded similar though slightly larger
results for the effect of the treatments.
With our assumption that the effect of the treatment is linearly related with
an individual’s predicted mortality probability, the estimates suggests an average
mortality rate decline of approximately 68 percent (which is equal to the ratio
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θ3 / θ 2 ), which is similar to the results reported above for the RACTs28 and for
studies that had detailed clinical information on patients. It therefore appears that
our estimates do a good job of replicating the results for average impacts from
studies with superior data or with the benefits of randomization.29 This is true
despite the fact that sicker individuals clearly self-select into the treatment. And
in contrast to estimates from RACTs, our estimates allow us to estimate the extent
to which the effects of the treatments varied across individuals in a real-world
setting.
One important limitation with the RACTs described above is that they do
not consider the effect of new treatments on health care expenditures. This is an
important factor to consider when evaluating the value of any new medical
innovation and is the focus of the next section.
VI. The Impact of the New Treatments on Health Care Expenditures

A. Changes in the Distribution of Medicaid Expenditures
Theoretically, the effect of Epivir/PI on average short-term health care spending is
ambiguous. As shown in Figure 6, the release of Epivir/PI coincided with a
significant increase in spending on prescription drugs, which was presumably
driven both by the increase in use of ARVs and by the substantially higher prices
of the new treatments relative to their predecessors. But as this same figure
shows, spending on other categories of medical care declined during this same
period. Which of these two effects dominated is not clear.
In considering this issue, it is important to differentiate between
individuals eligible only for Medicaid and their counterparts eligible for both
Medicaid and Medicare. For this latter group, the Medicare program is the
primary payer for inpatient and outpatient care, though Medicaid does share the
cost for most services. Thus to the extent that Epivir/PI lowered spending on
other health care services, one would expect – all else equal – to see a smaller
decline (or a larger increase) in spending for those also “dual eligibles” who are
also insured by the Medicare program.
Figure 8 sheds some light on this issue. In this figure, we plot average
spending for dual eligibles and for their counterparts eligible only for Medicaid.
As the figure shows, in the period leading up to the fourth quarter of 1995, there
28

It is not strictly comparable to the RACT results because most of these studies considered the
effect of just protease inhibitors when combined with AZT and Epivir. This underscores the point
raised above that we are capturing the effect of a combination of treatments rather than of one
specific pharmaceutical treatment.
29
Of course the average impact could have differed for the Medicaid population if, for example,
they did not comply with the recommended treatment regimen as well as individuals in the
RACTs.
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were substantial differences in spending for the two groups. Specifically, in the
third quarter of 1995 average Medicaid spending was more than twice as high for
those only covered by Medicaid ($6242 versus $3037) and both of these trends
were fairly stable. But beginning in the fourth quarter of 1995, spending for dual
eligibles began to increase while the opposite occurred for those only covered by
Medicaid. By the final quarter of 1996, average spending for dual eligibles had
increased by 36 percent (to $4122) versus a 16 percent decline for Medicaid-only
recipients (to $5256). This latter change suggests that the new treatments more
than “paid for themselves” in the short term by reducing spending on other
categories of medical care. The benefits of this expenditure offset for dual
eligibles are not as apparent in our Medicaid data because most inpatient and
outpatient care for this group is financed by Medicare.30
Figure 8: Average Medicaid Expenditures: Dual Eligibles vs. Medicaid Only
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These trends in average spending may mask important changes in the
overall distribution of spending. In Table 5 we list five different percentiles (30 th,
50th, 70th, 90th, and 95th) in the distribution of Medicaid expenditures. If Epivir/PI
30

The short-term spending declines suggested by this time series and estimated in the next section
are qualitatively similar to the 10 percent average decline in spending estimated by Bozzette et al
(2001) for a non-Medicaid population. In a related study, Goldman et al (2001) estimate an
average expenditure reduction of 31 percent that is attributable to more generous coverage of
ARVs by state AIDS Drug Assistance Programs.
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did reduce the use of other health care services, one might expect to detect larger
declines in spending at the high end of the expenditure distribution. In contrast,
total spending might actually increase at the low end given that there would be
relatively few health care services to offset for this group. Consistent with this,
the data summarized in Table 5 reveals that spending at the 30th and 50th
percentiles increased by 71 and 42 percent, respectively, from the third quarter of
1995 to the fourth quarter of 1996. But during that same period, Medicaid
spending at both the 90th and the 95th percentiles declined by 24 percent. The
change at the 70th percentile lied between these two extremes, with a 12 percent
increase during the period. Thus, although there was very little change in average
spending during the period when Epivir/PI was rapidly diffusing, there was a
substantial change in the distribution of this spending.
Table 5: Trends in the Distribution of Medicaid Expenditures: 1994Q1-1997Q4
(1)

(2)

(3)

(4)

(5)

(6)

(7)

(8)

(9)

Quarter

Any
Epiv/PI

Mean

NonDuals

Duals

30th

50th

70th

90th

95th

1994Q1
1994Q2
1994Q3
1994Q4
1995Q1
1995Q2
1995Q3
1995Q4
1996Q1
1996Q2
1996Q3
1996Q4
1997Q1
1997Q2
1997Q3
1997Q4

0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
6.7%
28.5%
37.0%
44.5%
50.2%
52.8%
56.0%
55.3%
55.2%

5330
5183
5320
4783
5331
5190
5193
4973
5096
5037
4994
4841
4790
4803
4836
5011

6135
5984
6283
5703
6380
6225
6242
6019
5893
5743
5648
5256
5273
5157
5149
5398

3133
3088
3004
2572
2955
2986
3037
2937
3560
3703
3812
4122
4002
4257
4373
4460

648
584
617
604
695
652
637
651
788
889
924
1090
1149
1275
1257
1307

1643
1508
1574
1503
1775
1705
1737
1693
2045
2124
2275
2473
2610
2775
2770
2860

3792
3554
3698
3627
4100
3998
3939
3895
4209
4450
4345
4420
4369
4616
4715
4684

14653
14820
15245
13058
14646
14372
13910
13760
13042
13046
12035
10679
10643
10459
10154
10164

23623
22610
24546
22039
23059
22581
23658
22893
21622
20835
20049
18324
17888
16695
17814
19360

Table summarizes Medicaid expenditure data for individuals in the 24 percent CA sample with 1 or
more HIV/AIDS claims in current or previous quarter and still alive at the end of current quarter.
Excludes those with one or more months in a Medicaid managed care plan or in one of the eight
counties with a county-organized health system. Column (1) lists the fracton of individuals in the
sample with one or more claims for Epivir/PI in the quarter. Columns (2), (3), and (4) list average
Medicaid spending for all individuals in the sample, those eligible for Medicaid only, and those
eligible for Medicaid and Medicare, respectively. Columns (5) through (9) list expenditures at five
different points in the quarter specific Medicaid expenditure distribution. Expenditures are inflation
adjusted to November 2001 dollars.
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B. Individual Level Estimates
In this section, we present results from specifications analogous to (4) above,
though in this case we focus on Medicaid spending. Following previous research
(Manning et al, 1987), we use the log rather than the level of health care spending
as our outcome variable given that – as shown in Table 5 – spending is highly
skewed to the right.31 We focus on individuals only eligible for Medicaid (thus
excluding dual eligibles) given that our data does not include spending by the
Medicare program for dual eligibles when estimating specifications of the
following type:
(5) log(S j ,t +1 ) = σ 1 * E jt + σ 2 * Dˆ j ,t +1 + σ 3 * E jt * Dˆ j ,t +1 + ρX jt + ωt +1 + ξ j ,t +1
The parameters of particular interest in this equation are σ 1 and σ 3 , which
represent the main effect of Epivir/PI and the interaction of this effect with our
proxy for health status Dˆ j ,t +1 .
Given that relatively sicker patients were more likely to take Epivir/PI
following its release, one would expect that average Medicaid spending for
individuals who took these treatments was higher on average than for their
counterparts who did not. The results presented in the first column of Table 6
support this prediction, with a statistically significant estimate of 0.834 for σ 1
when no other covariates are included. This estimate declines when additional
covariates are included in the next four specifications, though it remains
significantly positive. This is not surprising given that Medicaid expenditures did
increase at most points in the distribution as shown in Table 5.
In the sixth specification we include the interaction of our treatment
indicator with our proxy for health status. As expected, the estimate for σ 3 is
negative and is statistically significant, suggesting that sicker patients experienced
a smaller increase in spending. According to the model, individuals with a
predicted mortality probability in excess of 27 percent experienced a decline in
spending. The estimates are similar in the final specification (7) in which we
include both dual eligibles and individuals eligible only for Medicaid and
therefore have a larger sample.32

31

The logarithmic transformation substantially reduces the skewness in the data that can produce
biased estimates given the assumption of a normally distributed error term. Given that more than
90 percent of the person-quarter observations in 1995 and 1996 have strictly positive spending and
there is little change in this fraction over time, we do not also consider the effect on the probability
of strictly positive spending as the Manning et al (1987) study does.
32
As was true for the mortality specifications, our results are qualitatively similar if we "freeze"
each patient's predicted mortality probability at its level in the fourth quarter of 1995 for
observations in 1996.
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The results in this section demonstrate that the introduction and rapid
diffusion of Epivir/PI in late 1995 and 1996 increased Medicaid spending for
relatively healthy patients and for individuals also eligible for the Medicare
program. Despite this, the substantial reductions in spending for the sickest
individuals more than offset this, so that average quarterly Medicaid spending in
our sample declined by more than 7 percent in the year following the release of
these treatments.
Table 6: The Heterogeneous Impact of Epivir/PI on Medicaid Expenditures

Any Epivir/PI

(1)

(2)

(3)

(4)

(5)

(6)

(7)

.834***
(.054)

.796***
(.054)

.682***
(.049)

.668***
(.049)

.633***
(.043)

.901***
(.058)

1.094***
(.049)

7.371***
(.358)

5.782***
(.323)

3.411***
(.308)

4.192***
(.361)

4.262***
(.351)

3.345***
(.463)

-4.617***
(.435)

HIV Severity

Any Epivir/PI *
HIV Severity
Previous HIV
Severity
# Observations
Quarter Effects?
R-squared
# Individuals
Demographic
Controls?
Utilization
Controls?
Quarters
Included

3.109***
(.390)

2.323***
(.369)

2.348***
(.359)

2.360***
(.333)

8846
Yes
0.0395
2265

8846
Yes
0.0510
2265

8846
Yes
0.1575
2265

8846
Yes
0.1677
2265

8846
Yes
0.2683
2265

8846
Yes
0.2723
2265

14347
Yes
0.2983
3196

No

Yes

Yes

Yes

Yes

Yes

Yes

No
95Q196Q4

No
95Q196Q4

No
95Q196Q4

No
95Q196Q4

Yes
95Q196Q4

Yes
95Q196Q4

Yes
95Q196Q4

Sample includes all individuals with one or more HIV/AIDS claims in the quarter or in a previous
quarter and who are eligible for Medicaid in all three months of this quarter, all three months of the
previous quarter, and still alive at the end of the quarter. Unit of observation is the person-quarter.
Dependent variable is the log of Medicaid spending in the next period. The key explanatory variable
Any Epivir/PI is an indicator that equals one if an individual fills and Epivir or protease inhibitor
prescription in the quarter and zero otherwise. Standard errors are clustered by individual and included
in parentheses.
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VII. The Impact on Long-Term Medicaid Spending and the Cost per LifeYear Saved

In this section we simulate the impact of Epivir/PI on long-term health care
spending in the Medicaid program. There are two factors that diverge when
calculating these costs. First, our results suggest that average spending declined
when these treatments were introduced. In contrast, the large reduction in
mortality generated by Epivir/PI use increased life expectancy, and hence the
amount of time that individuals were eligible for Medicaid.33 In this section, we
build an illustrative model that allows us to capture these two opposing factors in
a simple calculation.
Consider an HIV positive patient that has progressed in their illness to the
point that physicians would recommend Epivir/PI use, which we label as quarter
0. Suppose in the absence of ARVs, a patient will have medical expenditures of
M0 in period 0, and for simplicity, assume this amount grows at a real rate of ρ per
quarter. Patients are assumed to die at a rate of δ in each quarter and this rate is
assumed to be constant over time. If r is the quarterly interest rate, the discounted
expected lifetime costs LT0 for this patient in the absence of antiretroviral
treatments are:
∞

(6) LTo = ∑ M 0[(1 + ρ ) /(1 + r )]t (1 − δ )t
t =0

For simplicity, assume that ρ is equal to r34 and therefore, that discounted lifetime
costs equal M0/δ. When Epivir/PI was introduced, assume baseline costs and the
mortality rates changed to M 0a and δa respectively, and therefore, lifetime costs
would then be M 0a /δa. The increase in life expectancy in quarters is simply [1/δa
– 1/δ] and the corresponding change in lifetime costs is [ M 0a /δa - M0/δ]. Dividing
this number by 4[1/δa – 1/δ] produces the cost per life year saved.
Prior to the introduction of the new treatments, the average quarterly
mortality rate in our sample was 7 percent and average spending per personquarter was equal to $6242. Our results from above suggest that Epivir/PI
reduced mortality rates by 68 percent and average Medicaid spending per quarter
33

As Meltzer (1997) outlines, there is some controversy about whether future medical costs
should be considered in medical cost-effectiveness studies. Meltzer argues that for costeffectiveness studies to be consistent with utility maximization, they must include all future
lifetime costs, including non-medical expenses. At the other extreme, others argue that only future
medical costs directly related to the illness should be included in these calculations. Given
available data, we examine all future medical costs but do not include non-medical expenses.
34
This assumption seems reasonable given that our estimate of the average growth rate in
individual-specific quarterly Medicaid spending in both the pre and post periods was
approximately 1 percent.
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by 16 percent. Given our simplifying assumptions, this implies that Epivir/PI
increased the average present value of Medicaid spending from $89,000 to
$234,000 and life expectancy from 3.6 to 11.2 years, with a corresponding cost
per life year saved of approximately $19,000.35 This is substantially lower than
recent estimates of the average individual's valuation of a life-year, which Cutler
and Richardson (1998) estimate lies between $75 thousand and $150 thousand.
We should note that we make a number of strong assumptions, including a
constant mortality rate (rather than one that increases over time) and that the
discount rate is equal to the growth in quarterly Medicaid expenditures. It is
worth noting, however, that the marginal cost per life year saved calculation is not
particularly sensitive to the assumed values of M0 and Ma0. If we assume there is
no change in spending associated with ARVs then the cost per life year saved
increases to roughly $25,000. Likewise, the results are not very sensitive to the
precise drop in mortality produced by ARVs. Thus even if we relax one of these
or our other assumptions, the four ARVs studied here are well within the range of
what is considered to be cost effective. 36
The estimates for this treatment do not apply to other ARVs or to other
new health care treatments. Indeed as shown in Figure 5, since the utilization of
Epivir/PI settled to its new equilibrium in early 1997, there has been little further
decline in mortality rates among Medicaid patients with HIV/AIDS. This has
been true despite a consistent increase in pharmaceutical spending in the last
several years of our sample, which increased from $2,385 in the second quarter of
1997 to almost $3,900 per quarter in 2001. However, before inferring anything
about cost-effectiveness from these simple trends, there are two important issues
to consider. First, mortality rates may have increased had it not been for the
arrival of the new ARVs, as the virus could have become more resistant to a
specific drug over time. Second, there may be other improvements in morbidity
that are not captured by mortality rates alone.37
35

This estimate is similar to estimates presented by Freedberg et al (2001). The authors use
estimates from RACTs to simulate the cost-effectiveness of three-drug anti-retroviral regimens.
They estimate that such a regimen costs $13,000 to $23,000 per quality adjusted life year in real
1998 dollars. The increase in life expectancy is just half as large as the 15 year impact simulated
by Philipson and Jena (2006) using the results from previous studies. However, their estimate
includes the increase in life expectancy from the time than an individual first contracts HIV. As
noted above, when individuals are first observed in our sample they may already have had HIV for
several years.
36
Our results further assume that the short term mortality and expenditure effects that we estimate
will persist in the long term. To the extent that the treatments become less effective over time,
lead to complications from other health conditions, and so forth, this assumption will not be
accurate.
37
While we have in this study focused on mortality, one could use the claims data to construct
measures of morbidity such as the presence of other conditions or time spent in inpatient care.
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VIII. Discussion

The steady increase in health care spending in recent years and that is projected
for the coming decades suggests that greater scrutiny may be given to the benefits
of new and more expensive health care treatments. Potential sources of data for
these analyses are the claims data sets from insurers such as Medicare, Medicaid,
or private insurance companies. These data sets have large sample sizes, have
detailed information on individuals’ treatments, and have very accurate data on
expenditures. It is, however, difficult to reliably estimate the effects of interest
with this data because of the absence of clinical information that would allow one
to control for baseline health status and because treatment decisions are
endogenous.
In this study we investigate whether the use of individual-level
administrative data from before and after the release of a new health care
treatment can be used to obtain credible estimates of its effect on both health care
spending and health outcomes and how this varies across individuals. Our
findings for the average treatment effects are in line with those from previous
studies that use randomized research designs or that have the benefit of detailed
clinical information. Specifically, our results suggest that the treatments led to a
68 percent reduction in mortality rates among the individuals who took them. In
contrast to these earlier studies, we can investigate the extent to which the use of
the treatments varies across individuals and how the effects of the treatments vary
as well. Additionally, we can consider the effect on health care expenditures.
When interpreting the results from our empirical analyses, it is important
to bear in mind a number of limitations. First, our model assumes that the effect
of ARVs is linearly related with our measure of health status. Second, to the
extent that unobserved factors are correlated with the ARV treatment decision,
our estimates will be biased. Third, changes in the observable characteristics of
those with HIV during our study period raise the possibility of composition bias.
Fourth, our estimates do not account for possible changes in the effectiveness of
ARVs over the long term. And finally, our estimates do not consider factors such
as firm R&D costs or treatment-induced changes in risky behavior, which
represent important components of a more comprehensive accounting of overall
treatment benefits and costs.
But the results from our primary specifications, combined with the trends
in mortality and in the distribution of Medicaid spending, strongly suggest that
one can use readily available administrative data from a real-world setting to
There will inevitably be certain measures of health status that one cannot capture in claims data,
and the importance of this limitation will depend on the treatment being considered.
DOI: 10.2202/1558-9544.1102
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obtain credible estimates of the effect of new treatments on both health care
spending and health outcomes and how these effects vary across individuals. An
important benefit of using data from before and after the introduction of new
treatments is that one can examine how the distribution of key outcome variables
evolves as the treatments diffuse, and use this as a check on the individual-level
estimates. Our approach is most well-suited to the evaluation of treatments that
diffuse rapidly and that are likely to affect health status primarily in ways that can
be captured in administrative data.

Appendix Figure 1: Rate of Non-Mortality Exit for Medicaid HIV/AIDS Sample
3.0%

2.5%

2.0%

Permanent
Temporary

1.5%

1.0%

0.5%

0.0%
1993.1

1994.1

1995.1

1996.1

1997.1

1998.1

1999.1

2000.1

2001.1

Year.Quarter

33

Brought to you by | University of Pennsylvania
Authenticated
Download Date | 6/1/16 4:09 PM

Forum for Health Economics & Policy, Vol. 11 [2008], Iss. 2, Art. 1

References

Bhattacharya, J., D. Goldman, and N. Sood, 2003. "The Link between Public and
Private Insurance and HIV-Related Mortality," Journal of Health
Economics 22(6): 1105-1122.
Bozzette, S., et al., 2001. “Expenditures for the Care of HIV-Infected Patients in
the Era of Highly Active Antiretroviral Therapy.” New England Journal
of Medicine 344: 817-823.
CASCADE Collaboration, 2003. “Determinants of survival following HIV-1
Seroconversion After the Introduction of HAART,” The Lancet
362(9392): 1267-74.
Chan, T. and B. Hamilton, 2006. “Learning, Private Information, and the
Economic Evaluation of Randomized Experiments.” Journal of Political
Economy 114(6): 997-1040.
Congressional Budget Office, 2006. “CBO’s Current Budget Projections (as of
January 26, 2006).” Available at http://www.cbo.gov/budget/budproj.pdf.
Cutler, D. and E. Richardson, 1998. “The Value of Health: 1970-1990.” AEA
Papers and Proceedings 88(2): 97-100.
Cutler, D.M., 2004. Your Money or Your Life: Strong Medicine for America’s
Health Care System, (New York, NY: Oxford University Press).
Delta Coordinating Committee, 2001. “Evidence for Prolonged Clinical Benefit
from Initial Combination Antiretroviral Therapy:
Delta Extended
Followup,” HIV Medicine 2(3): 181-188.
Detels, R., et al.,1998. “Effectiveness of Potent Antiretroviral Therapy on Time
to AIDS and Death in Men with Known HIV Infection Duration," Journal
of the American Medical Association 280(17): 1497-1503.
Duggan, M., 2005. "Do New Prescription Drugs Pay for Themselves? The Case
of Second-Generation Anti-Psychotics,” Journal of Health Economics
24(1): 1-31.
Eichner, J., and J.G. Kahn, 2001. “Coordination of Health Coverage for Medicare
Enrollees: Living with HIV/AIDS in California,” The National Academy

DOI: 10.2202/1558-9544.1102

Brought to you by | University of Pennsylvania
Authenticated
Download Date | 6/1/16 4:09 PM

34

Duggan and Evans: Estimating the Impact of Medical Innovation: A Case Study of ARVs

of Social Insurance, Medicare Brief, No. 8. Available at
http://www.nasi.org/usr_doc/medicare_brief_8.pdf.
Floridia, M., et al., 2002. “HIV-Related Morbidity and Mortality in Patients
Starting Protease Inhibitors in Very Advanced HIV Disease,” HIV
Medicine, 3(2): 75-84.
Freedberg, K.A., et al., 2001. “The Cost Effectiveness of Combination
Antiretroviral Therapy for HIV Disease,” The New England Journal of
Medicine, 344(11): 824-31.
Fuchs, Vincent R, 2004. “Perspective: More Variation In Use Of Care, More FlatOf-The-Curve Medicine,” Health Affairs (October 7). (Web Exclusive)
Garber, A., C. Jones, and P. Romer, 2006. "Insurance and Incentives for Medical
Innovation." Forum for Health Economics and Policy (Biomedical
Research and the Economy) 9(2): 4.
Garber, A., 2004. Cost-Effectiveness and Evidence Evaluation as Criteria for
Coverage Policy. Health Affairs (May 19). (Web Exclusive)
Ghosh, A. , N. Sood, and A. Leibowiz, 2007. "The Effect of State Cost
Containment Strategies on the Insurance Status and Use of Antiretroviral
Therapy (HAART) for HIV-Infected People." Forum for Health
Economics and Policy (Economics of the HIV Epidemic) 10(2): 3.

Goldman, D., et al., 2001. "Effect of Insurance on Mortality in an HIV-Positive
Population in Care," Journal of the American Statistical Association
96(455): 883-894.
Goldman, D., et al., 2001. “The Impact of State Policy on the Costs of HIV
Infection.” Medical Care Research and Review 58 (1): 31-53.
Hammer, S.M., et al., 1997. “A Controlled Trial of Two Nucleoside Analogues
Plus Indinavir in Persons with Human Immunodeficiency Virus Infection
and CD4 Cell Counts of 200 per Cubic Millimeter or Less,” The New
England Journal of Medicine 337(11): 725-33.

35

Brought to you by | University of Pennsylvania
Authenticated
Download Date | 6/1/16 4:09 PM

Forum for Health Economics & Policy, Vol. 11 [2008], Iss. 2, Art. 1

Kessler, D. and M. McClellan, 1996. "Do Doctors Practice Defensive Medicine?"
Quarterly Journal of Economics 111(2): 353-390.
Lakdawalla, D., N. Sood, and D. Goldman, 2006. “HIV Breakthroughs and Risky
Sexual Behavior,” Quarterly Journal of Economics 121(3): 1063-1102.
Lichtenberg, F., 2003. "The Effect of New Drug Approvals on HIV Mortality in
the U.S., 1987-1998," Economics and Human Biology 1(2): 259-266.
Lichtenberg, F., 2001. "Are the Benefits of Newer Drugs Worth their Costs?"
Health Affairs 20(5): 241-251.
Malani, A., 2006. “Identifying Placebo Effects with Data from Clinical Trials.”
Journal of Political Economy 114(2): 236-256.
Manning, W, et al., 1987. "Health Insurance and the Demand for Medical Care:
Evidence from a Randomized Experiment." American Economic Review
77(1987): 251-277.
Meltzer, David, 1997. "Accounting for Future Costs in Medical CostEffectiveness Analysis," Journal of Health Economics 16: 33-64.
Morin, S.F., et al., 2002. “Responding to Racial and Ethnic Disparities in use of
HIV drugs: Analysis of State Policies,” Public Health Reports 117(3):
263-72.
National Institutes of Health, 2004. “Guidelines for the Use of Antiretroviral
Agents in HIV-Infected Adults and Adolescents," Available at
http://www.aidsinfo.nih.gov//guidelines/adult/AA_102904.pdf
Newhouse, J., 1992. “Medical care costs: How much welfare loss?” The Journal
of Economic Perspectives 6(3): 3-21.
Palella, F.J. Jr, et al., 1998. “Declining Morbidity and Mortality Among Patients
with Advanced Human Immunodeficiency Virus Infection. HIV
Outpatient Study Investigators,” The New England Journal of Medicine
338(13): 853-60.
Petrin, Amil, 2002. "Quantifying the Benefits of New Products: The Case of the
Minivan." Journal of Political Economy 110: 705-729.

DOI: 10.2202/1558-9544.1102

Brought to you by | University of Pennsylvania
Authenticated
Download Date | 6/1/16 4:09 PM

36

Duggan and Evans: Estimating the Impact of Medical Innovation: A Case Study of ARVs

Philipson, T. and A. Jena, 2006. "Who Benefits from New Medical Technologies?
Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs,"
Forum for Health Economics and Policy (Biomedical Research and the
Economy) 9(2): 3.
Raffi, F., et al., 2001. APROCO Study Group. Anti-protease cohort. “Progression
to AIDS or Death as Endpoints in HIV Clinical Trials,” HIV Clinical
Trials 2(4): 330-5.
Rosenblum, L., et al., 1993. “HIV Infection in Hospitalized Patients and Medicaid
Enrollees: The Accuracy of Medical Record Coding,” American Journal
of Public Health 83(10): 1457-9.
Shapiro, M.F., et al., 1999. “Variations in the Care of HIV-Infected Adults in the
United States: Results from the HIV Cost and Services Utilization Study,”
Journal of the American Medical Association 281(24): 2305-15.
Yeni, P.G., et al., 2002. “Antiretroviral Treatment for Adult HIV Infection In
2002: Updated Recommendations of International AIDS Society–USA
Panel,” Journal of the American Medical Association 288(2): 222–35.

37

Brought to you by | University of Pennsylvania
Authenticated
Download Date | 6/1/16 4:09 PM

